The market is segmented based on , By Type (Immunoglobulin G (IgG) such as Molecule and Non Immunoglobulin G (IgG) such as Molecule), Mechanism of Action (Bispecific Diabodies and Bispecific T-Cell Engager Antibodies), Application (Oncology, Autoimmune Disease and Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies) – Industry Trends and Forecast to 2030.
.
The Global Bispecific Antibody Market size was valued at USD 545.00 USD Million in 2022.
The Global Bispecific Antibody Market is projected to grow at a CAGR of 6.9% during the forecast period of 2023 to 2030.
The major players operating in the market include Adimab, Innovent BiologicsInc , Affimed GmbH , Amgen Inc , AstraZeneca , Xencor , Sanofi , F. Hoffmann-La Roche Ltd , Regeneron Pharmaceuticals Inc , Lilly , Pieris PharmaceuticalsInc , Mereo BioPharma Group plc , Sobi, TG Therapeutics Inc , Merus , MacroGenicsInc , Genmab A/S , Emergent BioSolutions Inc , Alteogen , Astellas Pharma Inc , Novartis AG and CELGENE CORPORATION .
The market report covers data from the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of the Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.